Best Practice Handout – Health Plan Best Practice – Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

Topic(s):

Market Insights , Cancer – Non-Small Cell Lung Cancer (NSCLC)

Summary Framework for Improving Precision Oncology in NSCLC Findings From The AMCP Market Insights Program

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.

For more disease state research, view the Market Insights Program.